RUS  ENG
Полная версия
ЖУРНАЛЫ // Mendeleev Communications // Архив
Mendeleev Commun., 2012, том 22, выпуск 6, страницы 287–289 (Mi mendc2822)
Эта публикация цитируется в 2 статьях

Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

T. V. Rakitinaab, A. A. Zeifmancd, I. Yu. Titovcd, I. Svitankod, A. V. Lipkinbe, V. S. Stroylovcd, O. V. Stroganovcd, F. N. Novikovcd, G. G. Chilovcd

a M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
b National Research Centre 'Kurchatov Institute', Moscow, Russian Federation
c MolTech Ltd, Moscow, Russian Federation
d N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
e A.N. Bach Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russian Federation

Аннотация: Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.

Язык публикации: английский

DOI: 10.1016/j.mencom.2012.11.001


© МИАН, 2025